Spicy network SRMA, 123pts w/JAK-TNF-PLBO TNF >> JAK w/respect to malignancy (expected) & better than PLBO (spicy!) JAK > PLBO for heme cancers (makes sense); no significant (but slight trend) toward PLBO > JAK for all cancer The debate continues #ACR24 @RheumNow Abstr#0989 https://t.co/tBnb02gyzF

• https://x.com/EBRheum/status/1858188599910703531/photo/1

Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy

• Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab vers…
• https://x.com/RichardPAConway/status/1858190864708780251/photo/1

Abst #1473 evaluated association of SJC in PROs from 2 Bimekizumab trials (bDMARD naïve vs TNFi-IR) -bDMARD naïve had less SJC at baseline -In both groups, pts w lower SJC had sustained improvement in pain and fatigue over time. #ACR24 @RheumNow https://t.co/zwxsSbga7c

• https://x.com/AdelaCastro222/status/1858180798488424715/photo/1

Are biosimilar multi-switches an issue? real world data: DANBIO 🇩🇰 biosimilar to biosimilar switch having already had a switch prior ('previous ADAo') did not increase cessation The risk of biosimilar switching on immunogenicity is greatly overstated #ACR24 ABST1000 @RheumNow https://t.co/1yAfZrrNd0

• https://x.com/drdavidliew/status/1858180360288526800/photo/1

Single centre experience of belimumab at @GSTTnhs @RheumNow #ACR24 https://t.co/c4jlEPRwen

• https://twitter.com/sahilja09303150/status/1858168844587598111

#2282 🔬 Personalised Approach to TNFi in RA 📊 N=50👇; 43 responders 🔑 Findings 💥TNFR2 rs1061622 polymorphism linked to TNFi response 💥 MR/RR alleles ⬆️ 10X odds non-response v. MM allele (OR = 10.1,p=0.04) 🎯Genotyping may guide personalized RA therapy. #ACR24 @RheumNow https://t.co/MQKZUCEPxj

• https://x.com/CaoilfhionnMD/status/1858168467213475893/photo/1

#1474 🔬Severe PsA? Guselkumab (GUS) has promise! ➡️In bionaive pts with severe disease activity, GUS v. PBO resulted in: 🔴73% improvement in joints 🔴53% lower disease activity 🔴63% better PtGA by 2 years ➡️Rapid results by W2, sustained through W100. #ACR @RheumNow

Improved fertility in women with RA when treated with a Treat-to-Target (T2T) approach aimed at remission. Key findings: - Shorter time to pregnancy (TTP) in PreCARA cohort (84 days) vs. PARA cohort (196 days). - Increased TNF-inhibitor use and lower NSAID/prednisone use in the… https://t.co/YyD2lpXVRC https://t.co/LH5LMOH8al

• https://x.com/i/web/status/1858149341715698133
• https://x.com/synovialjoints/status/1858149341715698133/photo/1

The post hoc analysis of the SURPASS study evaluated predictors of radiographic spinal progression in axial spondyloarthritis patients treated with IL-17A (secukinumab) or TNF inhibitors over 2 years. Key findings: - New syndesmophytes: 18.2% (SEC 150 mg), 15.8% (SEC 300 mg),… https://t.co/jke6OHdPjZ

• https://x.com/i/web/status/1858151857870315827